SupplementPreliminary evidenceImmunity

Fisetin (senolytic)

Strawberry-derived flavonol with preclinical senolytic activity, human RCTs are just beginning; popularised by Mayo Clinic researchers.

Why

Fisetin is a flavonol found in strawberries (the richest source), apples, persimmons and onions. Mayo Clinic preclinical work (Yousefzadeh EBioMedicine 2018) identified fisetin as the most potent senolytic among 10 candidate flavonoids, clearing senescent cells in aged mice and extending healthspan. Human RCTs are at very early stages, the AFFIRM-LITE trial in frail elderly is published as a pilot. Outcome evidence is essentially preclinical-dependent at this stage.

How it works

Selectively induces apoptosis in senescent cells (SASP-secreting cells that accumulate with age), proposed senolytic mechanism. Independent antioxidant, anti-inflammatory, and Nrf2-modulating effects.

Expected onset · Outcome endpoints not yet clinically characterised

How to take

Dosage

Mayo Clinic intermittent protocol (preclinically-inspired): 20 mg/kg/day for 2 consecutive days, monthly. Lower daily doses (100–500 mg) used in some products.

Timing

With meals containing fat for absorption

On the label

Stated fisetin content per dose. Micronised, liposomal or novel-vehicle formulations have variable supporting evidence. Strawberries are the dietary source.

Ideal for

Adults exploring early-evidence senolytic approaches; people interested in concentrated flavonol supplementation beyond dietary intake.

Safety

Generally well tolerated in early trials. Pharmacology of intermittent high-dose senolytic protocols is not fully characterised, long-term effects not yet known. Caution with anticoagulants (mild antiplatelet effect). Pregnancy and breastfeeding: avoid (no data). Bioavailability is poor, micronised or liposomal forms claim improved absorption with limited validation.

Check interactions with my medications

Evidence

At a glance

Yousefzadeh 2018 EBioMedicine preclinical: fisetin extended lifespan and healthspan in aged mice via senolytic activity. Human RCT data is at very early pilot stage. Preliminary evidence, no Cochrane review, EMA HMPC monograph or EFSA-authorised health claim covers this indication; cited RCTs are small or in non-tier-1 journals. Useful as honest reference rather than evidence-grade recommendation. Senolytic supplementation is a frontier area; current evidence does not yet support routine recommendation.

Limitations

Outcome evidence is essentially preclinical-dependent. Human RCTs at very early stage. No Cochrane review, no EMA monograph, no EFSA-authorised claim. Bioavailability is poor.

Where to get it

Shop Fisetin (senolytic) on Amazon

Sponsored · As an Amazon Associate, Healicus earns from qualifying purchases.